Evidence map›Paper›PMID 31183659›Full record

ArticleInternational urology and nephrology2019

Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.

Shulin Wu, Sharron X Lin, Min Lu, Alexander O Subtelny, Zongwei Wang, Douglas M Dahl, Aria F Olumi, Chin-Lee Wu

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shulin WuDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Warren Building 225, 55 Fruit Street, Boston, MA, 02114, USA.
Sharron X LinDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Warren Building 225, 55 Fruit Street, Boston, MA, 02114, USA.
Min LuDepartment of Pathology, Peking University Health Science Center, Beijing, China.
Alexander O SubtelnyDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Warren Building 225, 55 Fruit Street, Boston, MA, 02114, USA.
Zongwei WangDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Warren Building 225, 55 Fruit Street, Boston, MA, 02114, USA.
Douglas M DahlDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Warren Building 225, 55 Fruit Street, Boston, MA, 02114, USA.
Aria F OlumiDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Chin-Lee WuDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Warren Building 225, 55 Fruit Street, Boston, MA, 02114, USA. cwu2@partners.org.ORCID http://orcid.org/0000-0002-0444-0068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the oncological impact of incidental prostate cancer (iPCa) found during radical cystoprostatectomy (RCP) on overall survival (OS) prognosis of urothelial carcinoma of the bladder (BCa). PATIENTS AND

methodsA total of 122 RCP cases resected between 2002 and 2012 at our center were included for study. Survival of BCa patient was compared using the Kaplan-Meier method and the log-rank test. Cox proportional hazards regression models were used to analyze the impact of iPCa on the 5-year overall mortality of BCa patients after RCP.

resultsAmong the 122 BCa cases that underwent RCP, 38 cases (31.1%) had iPCa, in which, 17 cases (44.7%) were identified as clinically significant iPCa (csPCa). BCa patients with iPCa were older (71 vs 64 years, p = 0.004) and had higher preoperative PSA level (3.1 ng/mL vs 1.4 ng/mL, p = 0.017) when compared to those without iPCa. Cases with iPCa showed a more favorable 5-year OS than cases without iPCa, although this difference did not reach statistical significance (p = 0.219). When excluding the higher risk cases with Gleason score (GS) ≥ 4 + 3 and/or preoperative PSA > 10 ng/mL, BCa patients with iPCa showed a significantly longer OS than cases without iPCa on univariate analysis (p = 0.044), but not on multivariate analysis (p = 0.125).

conclusionOur results demonstrated that the frequent findings of low-risk iPCa in BCa patients could indicate the potential possibility of shared pathogenesis pathways between iPCa and BCa. Future study with a larger cohort is warranted to validate this result.

Indexed as

CystectomyProstatectomyAgedAged, 80 and overCarcinoma, Transitional CellHumansIncidental FindingsMaleMiddle AgedPrognosisProstatic NeoplasmsSurvival RateTime FactorsUrinary Bladder NeoplasmsAndrogen receptorBladder cancerCystoprostatectomyIncidental prostate cancerPrognosis

Identifiers

PMID31183659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.